Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 3/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.71 |
| ▸ | MEN1 | O00255 | 3/20 | 0.71 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.64 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | NMBR | P28336 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5385762 | 1.00 | TACR1 (0.72) | TACR1KMT2AMEN1HCRTR1MAPT | |
| SCHEMBL5385757 | 1.00 | TACR1 (0.72) | TACR1KMT2AMEN1HCRTR1MAPT | |
| SCHEMBL29751620 | 0.91 | KMT2A (0.67) | TACR1KMT2AMEN1HCRTR1MAPT | |
| SCHEMBL468840 | 0.90 | KMT2A (0.71) | TACR1KMT2AMEN1HCRTR1MAPT | |
| SCHEMBL29401459 | 0.90 | KMT2A (0.71) | TACR1KMT2AMEN1HCRTR1MAPT | |
| SCHEMBL3184939 | 0.90 | KMT2A (0.71) | TACR1KMT2AMEN1HCRTR1MAPT | |
| SCHEMBL27703075 | 0.90 | KMT2A (0.71) | TACR1KMT2AMEN1HCRTR1MAPT | |
| SCHEMBL11369419 | 0.90 | ALOX15 (0.72) | TACR1KMT2AMEN1TP53 | |
| SCHEMBL14853055 | 0.90 | TACR1 (0.66) | TACR1KMT2AMEN1HCRTR1NPBWR1 | |
| SCHEMBL753982 | 0.90 | ALOX15 (0.72) | TACR1KMT2AMEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034216-A1 | STEREOSELECTIVE COVALENT LIGANDS FOR ONCOGENIC AND IMMUNOLOGICAL PROTEINS | THE SCRIPPS RESEARCH INSTITUTE | 2025-01-30 | — | — | US | disclosed |
| WO-2023092133-A1 | STEREOSELECTIVE COVALENT LIGANDS FOR ONCOGENIC AND IMMUNOLOGICAL PROTEINS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034216-A1 | STEREOSELECTIVE COVALENT LIGANDS FOR ONCOGENIC AND IMMUNOLOGICAL PROTEINS | CD2BP2, TP53, CD74 | TACR1 2805/4885KMT2A 1108/4885MEN1 3107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.